Conference Correspondent

The combination of nivolumab plus ipilimumab extended progression-free survival (PFS) versus stan­dard chemotherapy as first-line treatment for patients with advanced non–small cell lung cancer (NSCLC) with a high tumor mutational burden (TMB).
A burning question is whether immunotherapy combinations will further improve outcomes over checkpoint inhibitor therapy alone; and if so, which combinations will rise to the top.
People from lower socioeconomic backgrounds, minority groups, and rural areas are not well represented in clinical trials and biobanking, hampering research on health disparities.
The National Comprehensive Cancer Network has overhauled its guidelines for the management of colon and rectal cancers.
The updated guidelines from the National Comprehensive Cancer Network on the management of metastatic non–small cell lung cancer reflect the addition of osimertinib as a first-line option in patients with an epidermal growth factor receptor (EGFR)-sensitizing mutation and as subsequent therapy in patients whose disease progresses following another tyrosine kinase inhibitor if they develop a T790M resistance mutation.
The 40th anniversary of the San Antonio Breast Cancer Symposium was attended by approximately 8000 healthcare professionals and featured presentations ranging from basic science to preliminary clinical trials and new standards of care. Below is a summary of key presentations featured at the press conferences.
Older patients with hormone receptor–positive, HER2-negative, metastatic breast cancer derive similar benefit as younger patients treated with CDK4/6 inhibitors as part of initial endocrine therapy, according to a pooled analysis of registration trials presented at the 2017 San Antonio Breast Cancer Symposium.
At the 2017 Annual Meeting of the Multinational Association of Supportive Care in Cancer, Dr. Jeanne Carter shared research from her program at MSKDD to update attendees on current finding, newer assessment instruments, and clinical tools to identify sexual health concern in women with cancer.
Scalp cooling devices that allow patients treated with chemotherapy to retain their hair are used more commonly in Europe than in the United States, but this may be about to change now that the FDA has approved 2 scalp cooling devices: the DigniCap (approved in 2015) and the Paxman scalp cooling device (approved in 2017).
Page 2 of 4
Results 11 - 20 of 40

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country